Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ADMA vs CRSP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ADMA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

ADMA Overall Winner 6-Pillar Tally: ADMA 5 – 1 CRSP Matrix Metrics: ADMA 6 – 4 CRSP

As of Nov 16, 2026, ADMA Biologics, Inc. (ADMA) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ADMA carries a Unified Composite Score of 23.7/100 (STRONG SELL) at $13.70 (15.7x Forward P/E, 44.9% operating margin), whereas CRSP carries 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin).

  • Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. ADMA 23.7/100 STRONG SELL), ADMA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (44.9% vs. -2058.6% operating margin) and revenue trajectory (+5.1% vs. +1325.1% YoY).
  • Technical & Structure Timing Caution: ADMA trades in a Markup technical trend (SURGE options phase, RSI 71.1); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADMA vs CRSP
ADMA NASDAQ Head-to-Head Winner
ADMA Biologics, Inc.
Biological Products, (No Disgnostic Substances)
$13.70
+0.11% 1D
Market Cap $2.9B
TTM Revenue $519M
Forward P/E 15.7x
Beta / 30D Vol -0.42β · 99% Vol
Unified Composite Score
23.7 / 100 STRONG SELL
Tech 50.0 Fund 35.0 Flow 66.0 Mom 25.9
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.5% over 20 days), RSI 71
RSI-14: 71.1 · SMA20: $11.92 · SMA50: $10.66
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 30
RSI-14: 29.6 · SMA20: $48.84 · SMA50: $51.79

6-Pillar Scorecard Institutional Category Breakdown (ADMA 5 – 1 CRSP)

Columns: Metric · ADMA · CRSP
1. Valuation Multiples ADMA
Forward P/E 15.7x 23.4x
Trailing P/E 17.2x 23.4x
PEG Ratio N/M N/M
EV / Revenue 5.8x N/M
2. Growth & Scale CRSP
Revenue Growth (YoY) +5.1% +1325.1%
Earnings Growth (YoY) +46.7% +0.0%
TTM Revenue (USD) $519M $25M
Market Cap $2.9B $4.1B
3. Profitability & Quality ADMA
Gross Margin 68.5% N/A
Operating Margin 44.9% -2058.6%
Net Profit Margin 35.1% 0.0%
Return on Equity (ROE) 41.9% -25.6%
4. Balance Sheet & Cash Flow ADMA
Cash Generation (TTM) $133M -$378M
Cash Flow Margin 25.5% N/A
Net Cash / Leverage $78M Net Debt (0.46x D/E) $588M Net Debt (0.47x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ADMA
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 45.1% (8th %ile) 97.8% (52nd %ile)
Put/Call OI Skew 0.08x (Call-Skewed) 0.65x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ADMA
OpEx & R&D Intensity 23.6% of Rev ($123M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADMA (6) vs CRSP (4)
Institutional Metric ADMA CRSP Criterion Row Edge
Market Capitalization
Scale
$2.9B $4.1B Larger Scale CRSP
Trailing P/E Ratio
Valuation
17.2x 23.4x Lower Multiple ADMA
Forward P/E Ratio
Valuation
15.7x 23.4x Lower Multiple ADMA
Revenue Growth (YoY)
Growth
+5.1% +1325.1% Higher Growth CRSP
Operating Margin (TTM)
Profitability
44.9% -2058.6% Higher Margin ADMA
Net Profit Margin
Profitability
35.1% 0.0% Higher Margin ADMA
Return on Equity (ROE)
Capital Efficiency
41.9% -25.6% Higher ROE ADMA
52-Week Range Position
Momentum
49% ($7–$20) 1% ($40–$63) Stronger Trend ADMA
Beta / 30D Volatility
Risk Regime
-0.42β · 99% Vol 1.85β · 60% Vol Lower Realized Risk CRSP
Unified Institutional Score
Composite Signal
23.7 / 100 (STRONG SELL) 44.7 / 100 (HOLD) Higher Composite CRSP
Trailing 12M Revenue (USD)
Operating Scale
$519M $25M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$133M ($78M Net Debt (0.46x D/E)) -$378M ($588M Net Debt (0.47x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ADMA +45.77 pp
ADMA: +28.23% · CRSP: -17.54%
3M Horizon ADMA +66.88 pp
ADMA: +43.55% · CRSP: -23.33%
6M Horizon ADMA +79.79 pp
ADMA: +63.42% · CRSP: -16.37%
1Y Horizon ADMA +7.77 pp
ADMA: -12.77% · CRSP: -20.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ADMA Revenue CRSP Revenue ADMA Op. Margin CRSP Op. Margin Margin Leader
FY2018 $20M $0M -354.9% -5087.8% ADMA
FY2019 $30M $290M -141.1% 16.1% CRSP
FY2020 $40M $0M -153.8% -49295.5% ADMA
FY2021 $80M $910M -72.1% 40.8% CRSP
FY2022 $150M $0M -25.5% -56190.4% ADMA
FY2023 $260M $370M 8.4% -60.0% ADMA
FY2024 $430M $40M 32.6% -1250.4% ADMA
FY2025 $510M $0M 37.5% -18933.6% ADMA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADMA SURGE
7d in phase · OBV ACCUMULATION
Current IV 45.1%
IV Percentile 8th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ADMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADMA Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and 44.9% operating margin.
OpEx & R&D Reinvestment 23.6% of Rev ($123M)
90D Engineering Disclosures 0 Published
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ADMA vs CRSP Key Questions & Quantitative Answers

As of Nov 16, 2026, ADMA Biologics, Inc. (ADMA) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ADMA carries a Unified Composite Score of 23.7/100 (STRONG SELL) at $13.70 (15.7x Forward P/E, 44.9% operating margin), whereas CRSP carries 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin). Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. ADMA 23.7/100 STRONG SELL), ADMA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (44.9% vs. -2058.6% operating margin) and revenue trajectory (+5.1% vs. +1325.1% YoY). Technical & Structure Timing Caution: ADMA trades in a Markup technical trend (SURGE options phase, RSI 71.1); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRSP leads the Growth & Scale pillar: ADMA posts +5.1% YoY revenue growth and +46.7% YoY earnings growth on $519M TTM revenue (68.5% gross margin, 44.9% operating margin), compared with CRSP at +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ADMA cumulative revenue shifted +2450.0% while CRSP shifted -86.2%. In operating R&D and SG&A reinvestment, ADMA deploys 23.6% of Rev ($123M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRSP.

ADMA screens cheaper on headline valuation multiples. ADMA trades at 15.7x Forward P/E, 17.2x Trailing P/E, N/M PEG, and 5.8x EV/Revenue (25.5% FCF margin), whereas CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADMA (41.9% ROE) versus CRSP (-25.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ADMA carries 45.1% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (-0.42β · 99% Vol realized risk). By comparison, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.